Abstract: In vitro methods for predicting the response of a subject to autologous chimeric antigen receptor T-cell (CAR T-cell) therapy, the methods including determining the methylation status of one or more cytosines in CpG sites of CAR T-cells. Means and kits for carrying out the methods. With the determination of the methylation status of the one or more cytosines in CpG sites, a complete response free of events and long overall survival can be predicted as an outcome of the CAR T-cell therapy, in particular to subjects with B-cell malignancies.

Abstract: A nanoparticle material, a process for obtaining the nanoparticle material, a product that includes the nanoparticle material, and methods of using the nanoparticle material. The nanoparticle material includes a resorbable nanoparticle that is functionalized with at least one compound.

Abstract: Compounds derived from ursodeoxycholic acid of formula (I) and to methods for obtaining same, as well as the use thereof in the treatment of polycystic diseases, particularly autosomal dominant polycystic liver disease, autosomal dominant polycystic kidney disease, or autosomal recessive polycystic kidney disease.

Abstract: The present invention relates to compounds derived from ursodeoxycholic acid of formula (I), to methods for obtaining same, as well as the use thereof in the treatment of polycystic diseases, particularly autosomal dominant polycystic liver disease, autosomal dominant polycystic kidney disease, or autosomal recessive polycystic kidney disease.

Abstract: The present invention relates to compounds derived from ursodeoxycholic acid of formula (I), to methods for obtaining same, as well as the use thereof in the treatment of polycystic diseases, particularly autosomal dominant polycystic liver disease, autosomal dominant polycystic kidney disease, or autosomal recessive polycystic kidney disease.

Abstract: The present invention refers to the field of cancer and, in particular, to an in vitro method for the diagnosis of lung cancer by determining in a biological sample, taken from a subject, the methylation level of particular genes. It further relates to biomarkers and kits useful for said method.

Abstract: The invention relates to methods and reagents for the identification of the origin of a carcinoma of unknown primary origin (CUP) based on the determination of the methylation profile in the genome of the CUP. The invention relates as well to methods for selecting a suitable therapy for a patient suffering a CUP as well as to methods for personalized medicine of patient suffering a CUP based on the use of a treatment which is adequate for the primary tumor from which the CUP is derived. The invention also relates to kits comprising reagents adequate for performing the above methods as well as to computer systems and programs which can be used for implementing the methods of the invention.

Abstract: The invention relates to methods and reagents for the identification of the origin of a carcinoma of unknown primary origin (CUP) based on the determination of the methylation profile in the genome of the CUP. The invention relates as well to methods for selecting a suitable therapy for a patient suffering a CUP as well as to methods for personalized medicine of patient suffering a CUP based on the use of a treatment which is adequate for the primary tumor from which the CUP is derived. The invention also relates to kits comprising reagents adequate for performing the above methods as well as to computer systems and programs which can be used for implementing the methods of the invention.

Abstract: The invention describes new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases.

Abstract: The invention describes new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases.